SPRY
ARS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.11
−0.96%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.33
- Revenue estimate
- $42.8M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.63
- EPS estimate
- -$0.48
- Revenue actual
- $33.7M
- Revenue estimate
- $31.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -14.2%
- Revenue beats (12Q)
- 5
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.48 | -$0.63 | Miss -31.89% | $33.7M |
| May 15, 2026 | -$0.53 | -$0.61 | Miss -15.09% | $22.7M |
| Mar 9, 2026 | -$0.43 | -$0.42 | Beat 2.29% | $28.1M |
| Aug 13, 2025 | -$0.41 | -$0.46 | Miss -12.20% | $15.7M |
| May 14, 2025 | -$0.35 | -$0.35 | In line | $8.0M |
| Mar 20, 2025 | -$0.04 | $0.52 | Beat 1400.00% | $86.6M |
| May 9, 2024 | -$0.11 | -$0.11 | In line | — |
| Mar 21, 2024 | -$0.14 | -$0.07 | Beat 50.00% | $30.0K |
| Nov 9, 2023 | -$0.18 | -$0.16 | Beat 11.11% | — |
| Aug 10, 2023 | -$0.17 | -$0.18 | Miss -5.88% | $10.0K |
| May 15, 2023 | -$0.17 | -$0.16 | Beat 5.88% | $20.0K |
| Mar 23, 2023 | -$0.13 | $0.77 | Beat 692.31% | $1.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026